A neutralizing human anti-IL-17A antibody (secukinumab) has shown no results in moderate to severe CD, while a human anti-IL17 receptor A monoclonal antibody (brodalumab) improved active disease in CD in a randomized, double-blind clinical trial [45,46]. This evidence concerns the gene IL17A and Cowden disease.